This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EXAI Exscientia (EXAI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Exscientia Stock (NASDAQ:EXAI) 30 days 90 days 365 days Advanced Chart Get Exscientia alerts:Sign Up Key Stats Today's Range$4.84▼$4.8450-Day Range$4.69▼$5.9652-Week Range$3.80▼$6.49VolumeN/AAverage Volume713,050 shsMarket Capitalization$632.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom. Read More Receive EXAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EXAI Stock News HeadlinesExscientia and Recursion Merge to Revolutionize Drug DiscoveryNovember 21, 2024 | markets.businessinsider.comRecursion, Exscientia officially combine to advance drug discoveryNovember 21, 2024 | markets.businessinsider.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dollar portfolio today… Back then… one financial expert begged people to look at Nvidia -- when it was trading at just $1.10! Now… he’s urging you to look at a new group of seven stocks…September 1 at 2:00 AM | The Oxford Club (Ad)Recursion: No News Isn't Good News When It Comes To Vanilla PipelineNovember 20, 2024 | seekingalpha.comBarclays Sticks to Its Hold Rating for Exscientia Plc (EXAI)November 15, 2024 | markets.businessinsider.comRecursion and Exscientia Merger Approved by ShareholdersNovember 14, 2024 | markets.businessinsider.comRecursion Pharmaceuticals: Recursion and Exscientia Shareholders Approve the Proposed CombinationNovember 13, 2024 | finanznachrichten.deRecursion, Exscientia shareholders approve proposed combinationNovember 13, 2024 | markets.businessinsider.comSee More Headlines EXAI Stock Analysis - Frequently Asked Questions How were Exscientia's earnings last quarter? Exscientia plc (NASDAQ:EXAI) issued its quarterly earnings results on Thursday, August, 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.05. The business had revenue of $5.60 million for the quarter. Exscientia had a negative trailing twelve-month return on equity of 49.10% and a negative net margin of 882.09%. When did Exscientia IPO? Exscientia (EXAI) raised $291 million in an initial public offering on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share. What other stocks do shareholders of Exscientia own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exscientia investors own include AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/15/2024Today9/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EXAI CIK1865408 Webwww.exscientia.ai Phone44-0-18-6581-8941FaxN/AEmployees280Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$181.56 million Net Margins-882.09% Pretax Margin-904.93% Return on Equity-49.10% Return on Assets-33.13% Debt Debt-to-Equity Ratio0.06 Current Ratio4.54 Quick Ratio4.54 Sales & Book Value Annual Sales$25.60 million Price / Sales24.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.54 per share Price / Book1.91Miscellaneous Outstanding Shares130,770,000Free Float109,324,000Market Cap$632.93 million OptionableOptionable Beta0.83 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:EXAI) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exscientia plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Exscientia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.